ALLO News and Press, Allogene Therapeutics Inc. From 04/21/22

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and...

Allogene Therapeutics (NASDAQ:ALLO) unveiled its new manufacturing facility Cell Forge 1 located in Newark, California. The company said the 136K-square-foot facility will support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products f...

Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, California Cell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Modu...

Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic Malignancies ALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast Track Designation (FTD) by the U.S. FDA in March 2022 SOUTH SAN FRANCISCO, C...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in ...

Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at a new 52-week high of $54.80. So far today approximately 38.5 million shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares. In the past 52 weeks, Allogene Therapeutics Inc. share prices are brac...

ALLO-316 was given Fast Track Designation for the treatment of patients with renal cell carcinoma. It is expected that the global kidney cancer market could reach $9.4 billion by 2026. ALLO-647 is a lymphodepletion agent that Allogene has developed to possibly help the expansion a...

With the clinical hold having been lifted, Allogene is nearly back on track to lead the allogeneic CAR-T space. An excellent manufacturing capability helped lift the hold in just 3 months by developing a new kind of assay to track the chromosomal abnormality. Allogene is slowly de...

Gainers: RCM Technologies (RCMT) +17%. AppHarvest (APPH) +7%. Allogene Therapeutics (ALLO) +7%. Trevi Therapeutics (TRVI) +7%. Latch (LTCH) +5%. Losers: SVB Financial Group (SIVB) -17%. Expensify, Inc. (EXFY) -16%. Masimo Corporation (MASI) -10%. Fiesta Rest...

Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update E...